Entresto Tablet, Film Coated
Product Images NDC 71610-810

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Entresto (NDC 71610-810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 810 32)

The label for ENTRESTO film-coated tablets with the strength of 24 mg Sacubitril and 26 mg Valsartan. The package contains 780 tablets and includes storage instructions between 20-25 degrees Celsius, a National Drug Code (NDC) 71610-810-32, manufacturer details as Lek Pharmaceuticals d.d., packaging by Aphena Pharma Solutions - Tennessee, LLC, and a caution for Rx only use.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Valsartan Structural Formula (Entresto 01)

Chemical structure of the active ingredients Sacubitril and Valsartan shown with sodium ions and water of hydration. The diagram illustrates the molecular configuration of these combined compounds found in the ENTRESTO tablet.*

FDA Label Image

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)

A dot plot chart showing the geometric mean ratio and 90% confidence intervals for coadministered drugs with ENTRESTO (sacubitril and valsartan). The chart compares changes relative to reference for AUC and Cmax values of various drugs including furosemide, warfarin, digoxin, carvedilol, levonorgestrel, ethinyl estradiol, amlodipine, HCTZ, metformin, atorvastatin, and sildenafil.*

FDA Label Image

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)

A comparative chart showing geometric mean ratios and 90% confidence intervals for AUC and Cmax of LBQ657 and Valsartan across various population groups including renal and hepatic impairment levels, age, sex, and race. The x-axis displays change relative to reference, with data points represented by filled and open circles for LBQ657 and Valsartan respectively.*

FDA Label Image

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)

Three Kaplan-Meier survival curve graphs comparing ENTRESTO (Sacubitril and Valsartan) versus Enalapril in the PARADIGM-HF study. Figure A shows time to first occurrence of cardiovascular death or heart failure hospitalization. Figure B shows time to occurrence of cardiovascular death. Figure C shows time to first occurrence of heart failure hospitalizations. Each graph includes risk counts over time and hazard ratios with confidence intervals.*

FDA Label Image

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)

A forest plot chart comparing hazard ratios with 95% confidence intervals for various patient subgroups treated with ENTRESTO (sacubitril and valsartan) versus Enalapril. The subgroups include demographic factors, clinical parameters, and medical history. The X-axis ranges from 'ENTRESTO Better' to 'Enalapril Better' showing relative treatment effects.*

FDA Label Image

Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)

A line graph comparing total heart failure hospitalizations and cardiovascular deaths in the PARAGON-HF study. The x-axis shows time since randomization in days up to 1440 days. The y-axis shows the mean number of events per 100 patients. Two lines represent data for ENTRESTO and Valsartan, with ENTRESTO consistently showing fewer events over time.*

FDA Label Image

Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)

A forest plot chart showing rate ratio comparisons between ENTRESTO and Valsartan across various subgroups including age, gender, race, region, diabetes status, LVEF, AF history, NT-proBNP levels, SBP, MRA use, ACEI intolerance, baseline eGFR, and NYHA class. The plot includes point estimates with 95% confidence intervals and rates for each subgroup, with a horizontal axis indicating whether ENTRESTO or Valsartan performed better.*

FDA Label Image

Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)

This image shows two line graphs comparing the hazard ratios of ENTRESTO versus enalapril and ENTRESTO versus valsartan in relation to left ventricular ejection fraction at screening (%). Each graph includes a solid line for hazard ratio and dashed lines representing 95% confidence intervals across different ejection fraction percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.